The stock of Salarius Pharmaceuticals Inc (SLRX) has seen a 41.09% increase in the past week, with a 6.43% gain in the past month, and a -30.27% decrease in the past quarter. The volatility ratio for the week is 36.38%, and the volatility levels for the past 30 days are at 15.92% for SLRX. The simple moving average for the past 20 days is 19.36% for SLRX’s stock, with a -44.65% simple moving average for the past 200 days.
Is It Worth Investing in Salarius Pharmaceuticals Inc (NASDAQ: SLRX) Right Now?
Moreover, the 36-month beta value for SLRX is 0.98. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SLRX is 1.40M and currently, short sellers hold a 1.07% of that float. On October 22, 2024, SLRX’s average trading volume was 2.24M shares.
SLRX) stock’s latest price update
Salarius Pharmaceuticals Inc (NASDAQ: SLRX)’s stock price has plunge by -9.45relation to previous closing price of 2.01. Nevertheless, the company has seen a 41.09% surge in its stock price over the last five trading sessions. investorplace.com reported 2024-07-23 that Genomic therapeutic specialist Salarius Pharmaceuticals (NASDAQ: SLRX ) screamed higher Tuesday, with shares gaining 160% before paring back some of the gains to around 90%. Although no catalyst is apparent, the biotechnology firm revealed details about its at-the-market (ATM) offering recently.
Analysts’ Opinion of SLRX
Many brokerage firms have already submitted their reports for SLRX stocks, with Ladenburg Thalmann repeating the rating for SLRX by listing it as a “Buy.” The predicted price for SLRX in the upcoming period, according to Ladenburg Thalmann is $3.80 based on the research report published on April 27, 2020 of the previous year 2020.
SLRX Trading at 10.20% from the 50-Day Moving Average
After a stumble in the market that brought SLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.54% of loss for the given period.
Volatility was left at 15.92%, however, over the last 30 days, the volatility rate increased by 36.38%, as shares surge +10.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.87% lower at present.
During the last 5 trading sessions, SLRX rose by +41.09%, which changed the moving average for the period of 200-days by -62.71% in comparison to the 20-day moving average, which settled at $1.52. In addition, Salarius Pharmaceuticals Inc saw -65.00% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SLRX
Current profitability levels for the company are sitting at:
- -371.82 for the present operating margin
- 0.5 for the gross margin
The net margin for Salarius Pharmaceuticals Inc stands at -361.3. The total capital return value is set at -2.8. Equity return is now at value -119.83, with -82.83 for asset returns.
Currently, EBITDA for the company is 12884.89 with net debt to EBITDA at 0.49. When we switch over and look at the enterprise to sales, we see a ratio of -36.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.98.
Conclusion
To wrap up, the performance of Salarius Pharmaceuticals Inc (SLRX) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
